GlassScriptPhysician profile
Ronald Dean Kosanke
NPI 1033301866
$2,353.69
in general payments reported to CMS, 2019-2025
21 companies · $188 in 2025
The $188 reported for 2025 was less than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $590 · 2022: $503 · 2023: $623 · 2024: $450 · 2025: $188.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,244 · Education: $16.90.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,243.95 |
| Education | $16.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,053.85 | 2021-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $292.00 | 2022-2025 | |
| Lilly USA, LLC | $235.47 | 2021-2024 | Mounjaro, Zepbound |
| Novo Nordisk INC | $144.19 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $120.20 | 2021-2024 | Jardiance |
| Biohaven Pharmaceutical Holding Company LTD. | $67.14 | 2022 | |
| Genentech USA, INC. | $64.52 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $52.16 | 2021-2023 | Breztri |
| Merck Sharp & Dohme LLC | $39.31 | 2021 | |
| Mylan Specialty L.P. | $33.52 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $32.15 | 2024-2025 | Trulance, Xifaxan |
| Amgen INC. | $31.91 | 2025 | Repatha |
| Viatris Specialty LLC | $27.96 | 2025 | Yupelri |
| Biohaven Pharmaceuticals, INC. | $24.99 | 2021 | |
| Glaxosmithkline, LLC. | $24.98 | 2021 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $24.93 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $20.01 | 2022 | |
| Pfizer INC. | $18.10 | 2023 | |
| Axsome Therapeutics, INC. | $16.88 | 2025 | Auvelity |
| Astellas Pharma US INC | $15.62 | 2025 | Veozah |
| Shield Therapeutics INC | $13.80 | 2023 | Accrufer |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ronald Kosanke listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.